{"url_path":"/sec/nbix/8-k/2026-05-18/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/914475/0001193125-26-228013-index.html","accession_number":"0001193125-26-228013","cik":"0000914475","ticker":"NBIX","issuer_name":"NEUROCRINE BIOSCIENCES INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/914475/0001193125-26-228013-index.html","primary_entity_key":"0000914475","primary_entity_name":"NEUROCRINE BIOSCIENCES INC"},"word_count":310,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n \n\n(a)\n\nFinancial statements of businesses or funds acquired.\n\nThe Company intends to file the financial statements required by Item 9.01(a) of Form 8-K by an amendment to this Report no later than 71 calendar days after the date on which the initial Current Report on Form 8-K reporting completion of the Merger is required to be filed.\n\n \n\n(b)\n\nPro forma financial information.\n\nThe Company intends to file the pro forma financial information required by Item 9.01(b) of Form 8-K by an amendment to this Report no later than 71 calendar days after the date on which the initial Current Report on Form 8-K reporting completion of the Merger is required to be filed.\n\n \n\n4\n\n(d)\n\nExhibits.\n\n \n\nExhibit\n\nNumber\n\n  \n\nDescription\n\n 2.1*\n  \n[Agreement and Plan of Merger, dated April 5, 2026, by and among Neurocrine Biosciences, Inc., Sigma Merger Sub, Inc. and Soleno Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Neurocrine Biosciences, Inc. with the Securities and Exchange Commission on April 6, 2026)](http://www.sec.gov/Archives/edgar/data/914475/000119312526142904/d110123dex21.htm).\n\n10.1*\n  \n[Credit Agreement, dated May 14, 2026, among Neurocrine Biosciences, Inc., JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto.](d94926dex101.htm)\n\n99.1\n  \n[Press Release, dated May 18, 2026.](d94926dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n*\n\nCertain annexes, exhibits or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplemental copies of any of the omitted annexes, exhibits and schedules upon request by the U.S. Securities and Exchange Commission.\n\n \n\n5\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \nNEUROCRINE BIOSCIENCES, INC.\n\nDated: May 18, 2026\n \n\n \n\n \n\n/s/ Darin M. Lippoldt\n\n \n\n \n\n \n\n \nDarin M. Lippoldt\n\n \n\n \n\n \n\n \nChief Legal Officer\n\n \n\n6"}